At yesterday’s White House press briefing, both Donald Trump and Health and Human Services Secretary Alex Azar referenced two medications as “potential COVID-19 treatments.” For the administration, this wasn’t especially unusual: the president and his team have been talking up some anti-malaria drugs — chloroquine and hydroxychloroquine — quite a bit as the coronavirus crisis has intensified.
The underlying problem, however, remains the same. As a CNN report explained, Trump’s “over-the-top optimism” is not yet bolstered by the scientific research, “which is extremely limited and anecdotal at this early stage.”
On the surface, there are a variety of problems with the White House promoting unproven medications. It generates unnecessary confusion; it causes a run on drugs that many patients rely on; it can lead some to take dangerous risks through self-medicating, etc.
But late last week, Politico had a related report on this, noting another relevant angle: some health officials are “being pulled away from other potential projects to address the president’s hunch.”









